Maria Maccecchini

Company: Annovis Bio

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Exploring Opportunities in Alpha-Synuclein & Beyond for More Transformative & Efficacious Therapies: What’s Coming Next in Parkinson’s Drug Development? 4:30 pm

Taking learnings from targeting amyloid plaques, what is the rationale for targeting synuclein fibrils? What are the promising PD targets beyond alpha-synuclein? What can we expect to see in the next few years? What are the latest advancements in diagnostic tools like alpha-synuclein PET tracers and what potential do these hold? What are the earlier…Read more

day: Conference Day One PM

Highlighting Phase III Buntanetap Data & Embracing a More Holistic Approach to Neurodegenerative Disease Targeting 3:30 pm

Showcasing phase III success in improving cognition in Alzheimer’s disease (as measured by ADAScog) as well as movement and function in Parkinson’s (as measured by MDS-UPDRS) Outlining the cascade of events that follow Buntanetap-induced mRNA inhibition Leveraging its impact on several brain targets to emphasize the need for novel, more holistic drug approachesRead more

day: Conference Day One PM